Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate

A. Martinetti, E. Seregni, C. Ripamonti, L. Ferrari, F. De Conno, R. Miceli, F. Pallotti, A. Coliva, D. Biancolini, Emilio Bombardieri

Research output: Contribution to journalArticle

Abstract

A novel immunoassay specific for the osteoclast-produced TRAP isoform 5b has been developed recently. By means of this assay we studied the usefulness of serum TRAP-5b in monitoring the response to palliative treatment with pamidronate in breast cancer patients with bone metastases. We correlated serum TRAP-5b levels with pain intensity and intake of analgesics to assess the possible utility of the marker in identifying patients who could benefit from pamidronate treatment. Twenty-eight advanced breast cancer patients with bone metastases entered the study. Patients were treated according to the following schedule: two two-week cycles of 60 mg/week pamidronate IV, with a three-week interval in between (six infusions over seven weeks), followed by one infusion every three weeks for a total of 24 infusions over a treatment period of 61 weeks. Blood samples were taken before the start of treatment and before each infusion during two treatment cycles. To measure serum TRAP levels we employed the new immunoassay kit BoneTRAP® produced by Suomen Bioanalytiikka Oy (SBA), Oulu, Finland. In order to assess the usefulness of this marker in evaluating the response to pamidronate treatment we divided patients into two groups (group A, worsened; group B, improved) with respect to pain trend and analgesic intake. Our results did not show any statistically significant difference in baseline serum TRAP levels in the two groups. However, one week after the first pamidronate infusion TRAP-5b serum levels decreased by 39% and 18% in groups A and B, respectively (p=0.01); these levels persisted throughout the treatment period. In conclusion, a decrease in TRAP-5b serum levels may reflect the pharmacological activity of pamidronate and seems to predict pain relief and a reduction in analgesic consumption.

Original languageEnglish
Pages (from-to)253-258
Number of pages6
JournalInternational Journal of Biological Markers
Volume17
Issue number4
Publication statusPublished - Oct 2002

Fingerprint

pamidronate
Acid Phosphatase
Breast Neoplasms
Serum
Analgesics
Immunoassay
Pain
Bone
Therapeutics
Neoplasm Metastasis
Bone and Bones
Osteoclasts
Finland
Palliative Care
Tartrate-Resistant Acid Phosphatase
tartaric acid
Assays
Appointments and Schedules
Protein Isoforms
Blood

Keywords

  • Breast cancer metastases
  • Tartrate-resistant acid phosphatase-5b
  • TRAP-5b

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. / Martinetti, A.; Seregni, E.; Ripamonti, C.; Ferrari, L.; De Conno, F.; Miceli, R.; Pallotti, F.; Coliva, A.; Biancolini, D.; Bombardieri, Emilio.

In: International Journal of Biological Markers, Vol. 17, No. 4, 10.2002, p. 253-258.

Research output: Contribution to journalArticle

Martinetti, A. ; Seregni, E. ; Ripamonti, C. ; Ferrari, L. ; De Conno, F. ; Miceli, R. ; Pallotti, F. ; Coliva, A. ; Biancolini, D. ; Bombardieri, Emilio. / Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. In: International Journal of Biological Markers. 2002 ; Vol. 17, No. 4. pp. 253-258.
@article{ad0c0e3b72184ec8a01c1d6f890dc9d1,
title = "Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate",
abstract = "A novel immunoassay specific for the osteoclast-produced TRAP isoform 5b has been developed recently. By means of this assay we studied the usefulness of serum TRAP-5b in monitoring the response to palliative treatment with pamidronate in breast cancer patients with bone metastases. We correlated serum TRAP-5b levels with pain intensity and intake of analgesics to assess the possible utility of the marker in identifying patients who could benefit from pamidronate treatment. Twenty-eight advanced breast cancer patients with bone metastases entered the study. Patients were treated according to the following schedule: two two-week cycles of 60 mg/week pamidronate IV, with a three-week interval in between (six infusions over seven weeks), followed by one infusion every three weeks for a total of 24 infusions over a treatment period of 61 weeks. Blood samples were taken before the start of treatment and before each infusion during two treatment cycles. To measure serum TRAP levels we employed the new immunoassay kit BoneTRAP{\circledR} produced by Suomen Bioanalytiikka Oy (SBA), Oulu, Finland. In order to assess the usefulness of this marker in evaluating the response to pamidronate treatment we divided patients into two groups (group A, worsened; group B, improved) with respect to pain trend and analgesic intake. Our results did not show any statistically significant difference in baseline serum TRAP levels in the two groups. However, one week after the first pamidronate infusion TRAP-5b serum levels decreased by 39{\%} and 18{\%} in groups A and B, respectively (p=0.01); these levels persisted throughout the treatment period. In conclusion, a decrease in TRAP-5b serum levels may reflect the pharmacological activity of pamidronate and seems to predict pain relief and a reduction in analgesic consumption.",
keywords = "Breast cancer metastases, Tartrate-resistant acid phosphatase-5b, TRAP-5b",
author = "A. Martinetti and E. Seregni and C. Ripamonti and L. Ferrari and {De Conno}, F. and R. Miceli and F. Pallotti and A. Coliva and D. Biancolini and Emilio Bombardieri",
year = "2002",
month = "10",
language = "English",
volume = "17",
pages = "253--258",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate

AU - Martinetti, A.

AU - Seregni, E.

AU - Ripamonti, C.

AU - Ferrari, L.

AU - De Conno, F.

AU - Miceli, R.

AU - Pallotti, F.

AU - Coliva, A.

AU - Biancolini, D.

AU - Bombardieri, Emilio

PY - 2002/10

Y1 - 2002/10

N2 - A novel immunoassay specific for the osteoclast-produced TRAP isoform 5b has been developed recently. By means of this assay we studied the usefulness of serum TRAP-5b in monitoring the response to palliative treatment with pamidronate in breast cancer patients with bone metastases. We correlated serum TRAP-5b levels with pain intensity and intake of analgesics to assess the possible utility of the marker in identifying patients who could benefit from pamidronate treatment. Twenty-eight advanced breast cancer patients with bone metastases entered the study. Patients were treated according to the following schedule: two two-week cycles of 60 mg/week pamidronate IV, with a three-week interval in between (six infusions over seven weeks), followed by one infusion every three weeks for a total of 24 infusions over a treatment period of 61 weeks. Blood samples were taken before the start of treatment and before each infusion during two treatment cycles. To measure serum TRAP levels we employed the new immunoassay kit BoneTRAP® produced by Suomen Bioanalytiikka Oy (SBA), Oulu, Finland. In order to assess the usefulness of this marker in evaluating the response to pamidronate treatment we divided patients into two groups (group A, worsened; group B, improved) with respect to pain trend and analgesic intake. Our results did not show any statistically significant difference in baseline serum TRAP levels in the two groups. However, one week after the first pamidronate infusion TRAP-5b serum levels decreased by 39% and 18% in groups A and B, respectively (p=0.01); these levels persisted throughout the treatment period. In conclusion, a decrease in TRAP-5b serum levels may reflect the pharmacological activity of pamidronate and seems to predict pain relief and a reduction in analgesic consumption.

AB - A novel immunoassay specific for the osteoclast-produced TRAP isoform 5b has been developed recently. By means of this assay we studied the usefulness of serum TRAP-5b in monitoring the response to palliative treatment with pamidronate in breast cancer patients with bone metastases. We correlated serum TRAP-5b levels with pain intensity and intake of analgesics to assess the possible utility of the marker in identifying patients who could benefit from pamidronate treatment. Twenty-eight advanced breast cancer patients with bone metastases entered the study. Patients were treated according to the following schedule: two two-week cycles of 60 mg/week pamidronate IV, with a three-week interval in between (six infusions over seven weeks), followed by one infusion every three weeks for a total of 24 infusions over a treatment period of 61 weeks. Blood samples were taken before the start of treatment and before each infusion during two treatment cycles. To measure serum TRAP levels we employed the new immunoassay kit BoneTRAP® produced by Suomen Bioanalytiikka Oy (SBA), Oulu, Finland. In order to assess the usefulness of this marker in evaluating the response to pamidronate treatment we divided patients into two groups (group A, worsened; group B, improved) with respect to pain trend and analgesic intake. Our results did not show any statistically significant difference in baseline serum TRAP levels in the two groups. However, one week after the first pamidronate infusion TRAP-5b serum levels decreased by 39% and 18% in groups A and B, respectively (p=0.01); these levels persisted throughout the treatment period. In conclusion, a decrease in TRAP-5b serum levels may reflect the pharmacological activity of pamidronate and seems to predict pain relief and a reduction in analgesic consumption.

KW - Breast cancer metastases

KW - Tartrate-resistant acid phosphatase-5b

KW - TRAP-5b

UR - http://www.scopus.com/inward/record.url?scp=0036822195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036822195&partnerID=8YFLogxK

M3 - Article

C2 - 12521129

AN - SCOPUS:0036822195

VL - 17

SP - 253

EP - 258

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -